How HLA-DM affects the peptide repertoire bound to HLA-DR molecules

Human Immunology

Volumn 54, Issue 2, 1997, Pages 170-179

  Vogt, Anne B ^a   Kropshofer, Harald ^a   Hämmerling, Günter J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; DIMER; HLA DM ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL MUTANT; ENDOPLASMIC RETICULUM; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW;

ANTIGEN PRESENTATION; BIOLOGICAL TRANSPORT; CELLS, CULTURED; ENDOPLASMIC RETICULUM; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMANS; PEPTIDES;

EID: 0030770701     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00077-3     Document Type: Review

References (69)

1. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287, 1994.
2. Roche PA, Marks MS, Cresswell P: Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354:392, 1991.
3. Bakke O, Dobberstein B: MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 63:707, 1990.
4. Lotteau V, Teyton L, Péléraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA: Intracellular transport of class II MHC molecules directed by the invariant chain. Nature 348:600, 1990.
5. Roche PA, Cresswell P: Proteolysis of the MHC class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci USA 88:3150, 1991.
6. Marie MA, Taylor MD, Blum JS: Endosomal aspartic proteinases are required for invariant chain processing. Proc Natl Acad Sci USA 91:2171, 1994.
7. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P: HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474, 1992.
8. Romagnoli P, Germain RN: The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 180:1107, 1994.
9. Freisewinkel IM, Schenck K, Koch N: The segment of invariant chain that is critical for association with MHC class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 90:9703, 1993.
10. Vogt AB, Stern LJ, Amshoff C, Dobberstein B, Hämmerling GJ, Kropshofer H: Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR. J Immunol 155:4757, 1995.
11. Roche PA, Cresswell P: Invariant chain association with HLA-DR molecules inhibits immunogeneic peptide binding. Nature 345:615, 1990.
12. DeMars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM: Homozygous deletions that simultaneously eliminate expression of class I and class II antigens of EBV-transformed B-lymphoblastoid cells: reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol 11:77, 1984.
13. Ehrlich H, Lee JS, Petersen JW, Bugawan T, DeMars R: Molecular analysis of HLA class I and class II antigen loss mutants reveals a homozygous deletion of the DR, DQ and part of the DP regions: implications for class II gene order. Hum Immunol 16:205, 1986.
14. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D: Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 343:71, 1990.
15. Riberdy JM, Cresswell P: The antigen processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J Immunol 148:2586, 1992.
16. Sette A, Ceman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMars R: Invariant chain peptides in most HLA-DR molecules of an antigen processing mutant. Science 258:1801, 1992.
17. Avva R, Cresswell P: In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1:763, 1994.
18. Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ: Self-release of CLIP in peptide loading of HLA-DR molecules. Science 270:1357, 1995.
19. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E: An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368:551, 1994.
20. Fling SP, Arp B, Pious D: The HLA-DMA gene is required for the formation of stable class II/peptide complexes. Nature 368:554, 1994.
21. Kelly AP, Monaco JJ, Cho S, Trowsdale J: A new human HLA class II-related locus. Nature 353:571, 1991.
22. Cho S, Attaya M, Monaco JJ: New class II-like genes in the murine MHC. Nature 353:573, 1991.
23. Charrington M, Yeager M, Mann D: Characterization of HLA-DMB polymorphism. Immunogenetics 38:446, 1993.
24. Sanderson F, Powis SH, Kelly AP, Trowsdale J: Limited polymorphism in HLA-DM does not involve the peptide binding groove. Immunogenetics 39:56, 1994.
25. Sanderson F, Trowsdale J: Kissing cousins exchange CLIP. Curr Biol 5:1372, 1995.
26. Denzin LK, Cresswell P: HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 82:155, 1995.
27. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB: HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6:293, 1997.
28. Sanderson F, Kleijmeer M, Kelly A, Verwoerd D, Tulp A, Neefjes J, Geuze HJ, Trowsdale J: Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 266:1566, 1994.
29. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS: A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol 131:351, 1995.
30. Lindstedt R, Liljedahl M, Péléraux A, Peterson PA, Karlsson L: The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 3:561, 1995.
31. Karlsson L, Péléraux A, Lindstedt R, Liljedahl M, Peterson PA: Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science 266: 1569, 1994.
32. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM: Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802, 1995.
33. Sherman MA, Weber DA, Jensen P: DM enhances peptide binding to class II MHC by release of invariant chain-derived peptides. Immunity 3:197, 1995.
34. Mellins E, Cameron P, Amaya M, Goodman S, Pious D, Smith L, Arp B: A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med 179:541, 1994.
35. Sanderson F, Thomas C, Neefjes J, Trowsdale J: Association between HLA-DM and HLA-DR in vivo. Immunity 4:87, 1996.
36. Denzin LK, Hammond C, Cresswell P: HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 184:2153, 1996.
37. Schafer PH, Green JM, Malapati S, Gu L, Pierce SK: HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes. J Immunol 157:5487, 1996.
38. Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ: Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA 93:9724, 1996.
39. Flynn GC, Chappell TG, Rothman JE: Peptide binding and release by proteins implicated as catalysts of protein assembly. Science 245:385, 1989.
40. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ: Editing of the HLA-DR peptide repertoire by HLA-DM. EMBO J 15:6144, 1996.
41. Roche PA: HLA-DM: an in vivo facilitator of MHC class II peptide loading. Immunity 3:259, 1995.
42. Sette A, Southwood S, Miller J, Appella E: Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 181:677, 1995.
43. Weber DA, Evavold BD, Jensen PE: Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274:618, 1996.
44. Dornmair K, Rothenhäusler B, McConnell HM: Structural intermediates in the reactions of antigenic peptides with MHC molecules. Cold Spring Harbor Symp Quant Biol 54:409, 1989.
45. Verreck FAW, Vermeulen C, v d Poel A, Jorritsma P, Amons R, Coligan JE, Drijfthout JW, Koning F: The generation of SDS-stable HLA-DR dimers is independent of efficient peptide binding. Int Immunol 8:397, 1996.
46. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215, 1994.
47. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs A, Sinigaglia F: Promiscuous and allele-specific anchors in HLA-DR binding peptides. Cell 74:197, 1993.
48. van Ham SM, Grüneberg U, Malcharek G, Bröker I, Melms A, Trowsdale J: Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 184:2019, 1996.
49. Hammer J, Belunis C, Bolin D, Papadopoulos J, Walsky R, Higelin J, Danho W, Sinigaglia F, Nagy Z: High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Natl Acad Sci USA 91:4456, 1994.
50. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27, 1993.
51. Katz JF, Stebbins C, Appella E, Sant AJ: Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med 184:1747, 1996.
52. Kropshofer H, Hämmerling GJ, Vogt AB: How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 18:77, 1997.
53. Runnels HA, Moore JC, Jensen PE: A structural transition in class II major histocompatibility complex proteins at mildly acidic pH. J Exp Med 183:127, 1996.
54. Boniface JJ, Lyons DS, Wettstein DA, Allbritton NL, Davis MM: Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced. J Exp Med 183:119, 1996.
55. Devaux B, Wilson KJ, Aguilar B, Jorgensen B, Rothbard JB: Differential stability of HLA-DR alleles independent of endogenous peptides. J Immunol 155:1921, 1995.
56. Germain R, Hendrix LR: MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 353:134, 1991.
57. Sadegh-Nasseri S, Germain RN: A role for peptide in determining MHC class II structure. Nature 353:167, 1991.
58. Stern LJ, Wiley DC: The human MHC class II protein HLA-DR1 assembles as empty αβ-heterodimers in the absence of antigenic peptide. Cell 68:465, 1992.
59. Germain R, Rinker AG Jr: Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes selective cell surface expression of occupied molecules. Nature 363:725, 1993.
60. Ellis RJ, Hemmingsen SM: Molecular chaperones: proteins essential for the biogenesis of some macromolecular structures. Trends Biochem Sci 14:339, 1989.
61. Brooks AG, Campbell PL, Reynolds P, Gautam AM, McCluskey J: Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA-DM genes. J Immunol 153: 5382, 1994.
62. Stebbins CS, Loss GE Jr, Elias CG, Chervonsky A, Sant AJ: The requirement for DM in class II restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med 181:223, 1995.
63. Ma C, Blum JS: Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation. J Immunol 158:1, 1997.
64. Urban RG, Chicz RM, Strominger JL: Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J Exp Med 180:751, 1994.
65. Kropshofer H, Vogt AB, Hämmerling GJ: Structural features of invariant chain CLIP region controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acad Sci USA 92:8313, 1995.
66. Adams S, Humphreys RE: Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 25:1693, 1995.
67. Ghosh P, Amaya M, Mellins E, Wiley DC: The structure of HLA-DR3 complexed with CLIP, an intermediate in peptide loading. Nature 387:457, 1995.
68. Pinet V, Vergelli M, Martin R, Bakke O, Long EO: Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 375:603, 1995.
69. Liljedahl M, Kuwana T, Fung-Leung W-P, Jackson MR, Peterson PA, Karlsson L: HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 15:4817, 1996.